• With the pharmaceutical industry’s focus on oncology and more targeted therapies, the number of highly potent active pharmaceutical ingredients (HPAPIs) in development continues to increase. as does the demand for HPAPI manufacturing capacity.  Lonza has more than 20 years’ experience in the manufacture and handling of HPAPIs and offers expertise, capabilities, manufacturing innovation, and integrated service options.

  • Bringing Covid-19 therapeutic solutions to the clinic and market with speed, precision and scalability is now a challenge with unparalleled consequence. Ajinomoto Bio-Pharma Services remains committed to helping customers address the global demand for a solution.

  • This brochure provides an overview of Thermo Fisher Scientific’s biopharma capabilities. Download it to learn about their capabilities, integrated workflows, processes, and more.

  • Your programs deserve the most comprehensive suite of CDMO services available, and Ajinomoto Bio-Pharma Services has the Power To Make your therapeutic vision a reality — from pre-clinical through commercial production.

  • Enviero progesterone is the first compound launched from Pfizer CentreOne’s Enviero green-chemistry program and is being adopted across Pfizer providing the latest in lower environmental impact products for patients around the world.